Popular Articles
Stretch Mark Cream

New Method For Detecting Nitroxyl Will Boost Cardiac Drug Research
Wake Forest University scientists have developed a new research tool in the pursuit of heart medications based on the compound nitroxyl by identifying unique chemical markers for its presence in biological systems.
generic viagra online
Sen. Baucus To Meet With Single-Payer Reform Advocates Wednesday
The San Francisco Chronicle reports that Sen. Max Baucus, D-Mont., will meet with supporters of a single-payer health system Wednesday to discuss their ideas on health reform. Drugshop to buy zoloft online and other pills.
News of the day
White House Submits Sotomayor's Questionnaire To Senate Judiciary Committee
The Senate Judiciary Committee"s vetting of Judge Sonia Sotomayor, President Obama"s nominee for the Supreme Court, officially began Thursday when the White House delivered her written responses to a comprehensive questionnaire designed by the committee"s leadership, Roll Call reports. The questionnaire -- developed by Committee Chair Patrick Leahy (D-Vt.) and ranking member Jeff Sessions (R-Ala.) -- will be used as part of preparations for Sotomayor"s as-yet-unscheduled round of confirmation hearings (Stanton, Roll Call, 6/4).Sotomayor disclosed a large amount of information in the questionnaire, such as her net worth and a timeline for when she learned that she was under consideration by the White House as a potential replacement to retiring Supreme Court Justice David Souter (Perine, CQ Today, 6/4). According to Roll Call, Sotomayor"s responses might offer members of both parties "fodder to support or oppose her nomination."Leahy, who has the authority to schedule the confirmation hearings, said in a statement that Sotomayor "has advanced the confirmation process by promptly complying with this Senate requirement, and now the Senate should promptly schedule hearings to fairly consider her nomination to our highest court," adding, "The unfair attacks that have been leveled at her from outside the Senate are all the more reason to give her the chance to respond." Earlier this week, he said that he would announce a start date for the hearings after Sotomayor"s responses were received (Roll Call, 6/4). Meanwhile, Sotomayor on Thursday continued another round of private meetings with senators on Capitol Hill, including a few GOP senators who earlier had expressed concerns about her past comments and actions, CQ Today reports (CQ Today, 6/4).Questions Over Sotomayor"s Position on Abortion-Rights Issue RemainIn related news, USA Today on Friday examined how Sotomayor in the past 17 years as a federal judge "has left no clear footprints revealing" her position on abortion-rights issues. This week, some Democratic senators in private meetings with Sotomayor attempted to seek answers, while advocates on both sides of the debate are urging senators to question her about her views on Roe v. Wade during the expected confirmation hearings. On Wednesday, following a meeting with Sotomayor, Sen. Dianne Feinstein (D-Calif.) said that she believes Sotomayor has respect for judicial precedent. Nancy Northup, president of the Center for Reproductive Rights, said, "I don"t have concerns about this nominee in the sense that I think there is something on the record (against abortion rights)," adding, "We just think it"s important for Supreme Court nominees to say where they stand." Charmaine Yoest, president of Americans United for Life, agreed, noting the lack of a definitive position on abortion rights in Sotomayor"s record. Feinstein also said that she will persist on abortion-rights issues. "I remember what it was like when abortion was illegal, and the lives of young, desperate women were in jeopardy," she said, adding that she is concerned "Americans no longer appreciate what it would mean if (abortion rights) were taken away" (Biskupic, USA Today, 6/5).
Nutrition

Certain Cold Remedies Linked To Loss Of Sense Of Smell Warns FDA

The US Food and Drug Administration (FDA) advised consumers yesterday not to use certain cold remedies under the Zicam label because they have received over 100 reports linking the products to loss of sense of smell (anosmia) which can be long-lasting or permanent. The products in question are marketed as three over the counter remedies: *Zicam Cold Remedy Nasal Gel, *Zicam Cold Remedy Nasal Swabs, and *Zicam Cold Remedy Swabs, Kids Size (now discontinued). The FDA said they had received over 130 reports of loss of sense of smell linked to the use of these products. The reports go back to 1999, when Matrixx Initiatives, based in Scottsdale, Arizona, first started marketing the intranasal zinc products. Many of the people affected said they lost their sense of smell with the first dose, others said it was after several doses. Director of the FDA"s Center for Drug Evaluation and Research (CDER), Dr Janet Woodcock said: "Loss of sense of smell is a serious risk for people who use these products for relief from cold symptoms." "We are concerned that consumers may unknowingly use a product that could cause serious harm, and therefore we are advising them not to use these products for any reason." According to the New York Times, this move signals a new approach by the FDA under the new Obama administration to be more aggressive than the previous president in enforcing action against drug companies. The paper also reported that in 2006, Matrixx paid out 12 million dollars to settle over 300 lawsuits from consumers who had used Zicam and claimed that it had ruined their sense of smell. There are reported to be hundreds more lawsuits waiting. Matrixx have refused to recall the product, which is very unusual for a drug company, although it has suspended further shipments and said in a statement they would reimburse customers seeking a refund. The FDA has no official power to order companies to recall products, it can only ask them to do so, and in the vast majority of cases they do. In a news release the company refused to acknowledge a "causal link" between its products and loss of sense of smell and called the FDA action "unwarranted". Representatives of the company are hoping to meet with FDA officials to review the product safety data, said the statement. Because Zicam products are classed as homeopathic they didn"t have to have FDA approval before being sold over the counter. However, the federal agency said yesterday that they have written a warning letter to Matrixx, telling them that "these products cannot be marketed without FDA approval". Director of the Office of Compliance at the FDA"s CDER, Deborah M Autor, told the press that Matrixx had received more than 800 reports from Zicam consumers who said they had lost their sense of smell, but the company did not forward them to the FDA, reported the New York Times. Zinc can be toxic to nerve receptors in the nose, Dr Charles E Lee, a compliance officer with the CDER, told the paper. Autor said losing one"s sense of smell was "disabling" in several ways: "People without the sense of smell may not be able to detect dangers such as gas leaks or smoke. They could lose much of the pleasure of eating, adversely impacting the quality of life," she explained. The FDA asked that anyone who has lost their sense of smell or experienced any other problems from using one of the affected Zicam products should see their doctor. Consumers and health professionals should report any adverse events to the FDA MedWatch Adverse Event Reporting system, they said. -- FDA s: FDA, New York Times. Written by: Catharine Paddock, PhD Copyright: Medical News Today Not to be reproduced without permission of Medical News Today


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):